Publication: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against hiv-1
Issued Date
2021-09-01
Resource Type
ISSN
2050084X
Other identifier(s)
2-s2.0-85116328012
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
eLife. Vol.10, (2021)
Suggested Citation
Shida Shangguan, Philip K. Ehrenberg, Aviva Geretz, Lauren Yum, Gautam Kundu, Kelly May, Slim Fourati, Krystelle Nganou-Makamdop, Latonya D. Williams, Sheetal Sawant, Eric Lewitus, Punnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Supachai Rerks-Ngarm, Morgane Rolland, Daniel Douek, Peter Gilbert, Georgia D. Tomaras, Nelson Michael, Sandhya Vasan, Rasmi Thomas Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against hiv-1. eLife. Vol.10, (2021). doi:10.7554/eLife.69577 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76036
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against hiv-1
Author(s)
Shida Shangguan
Philip K. Ehrenberg
Aviva Geretz
Lauren Yum
Gautam Kundu
Kelly May
Slim Fourati
Krystelle Nganou-Makamdop
Latonya D. Williams
Sheetal Sawant
Eric Lewitus
Punnee Pitisuttithum
Sorachai Nitayaphan
Suwat Chariyalertsak
Supachai Rerks-Ngarm
Morgane Rolland
Daniel Douek
Peter Gilbert
Georgia D. Tomaras
Nelson Michael
Sandhya Vasan
Rasmi Thomas
Philip K. Ehrenberg
Aviva Geretz
Lauren Yum
Gautam Kundu
Kelly May
Slim Fourati
Krystelle Nganou-Makamdop
Latonya D. Williams
Sheetal Sawant
Eric Lewitus
Punnee Pitisuttithum
Sorachai Nitayaphan
Suwat Chariyalertsak
Supachai Rerks-Ngarm
Morgane Rolland
Daniel Douek
Peter Gilbert
Georgia D. Tomaras
Nelson Michael
Sandhya Vasan
Rasmi Thomas
Other Contributor(s)
Faculty of Tropical Medicine, Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
HJF
Walter Reed Army Institute of Research
National Institutes of Health (NIH)
Duke University School of Medicine
Fred Hutchinson Cancer Research Center
Emory University
Chiang Mai University
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
HJF
Walter Reed Army Institute of Research
National Institutes of Health (NIH)
Duke University School of Medicine
Fred Hutchinson Cancer Research Center
Emory University
Chiang Mai University
Abstract
A gene signature previously correlated with mosaic adenovirus 26 vaccine protection in simian immunodeficiency virus (SIV) and SHIV challenge models in non-human primates (NHP). In this report we investigated presence of this signature as a correlate of reduced risk in human clinical trials and potential mechanisms of protection. The absence of this gene signature in the DNA/rAd5 human vaccine trial, which did not show efficacy, strengthens our hypothesis that this signature is only enriched in studies that demonstrated protection. This gene signature was enriched in the partially effective RV144 human trial that administered the ALVAC/protein vaccine, and we find that the signature associates with both decreased risk of HIV-1 acquisition and increased vaccine efficacy. Total RNA-seq in a clinical trial that used the same vaccine regimen as the RV144 HIV vaccine implicated antibody-dependent cellular phagocytosis (ADCP) as a potential mechanism of vaccine protection. CITE-seq profiling of 53 surface markers and transcriptomes of 53,777 single cells from the same trial showed that genes in this signature were primarily expressed in cells belonging to the myeloid lineage, including monocytes, which are major effector cells for ADCP. The consistent association of this transcriptome signature with vaccine efficacy represents a tool both to identify potential mechanisms, as with ADCP here, and to screen novel approaches to accelerate development of new vaccine candidates.